KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2016 - 2025)

Rigel Pharmaceuticals has reported Other Accumulated Expenses over the past 16 years, most recently at $11.5 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 2.43% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, down 2.43%, while the annual FY2025 figure was $11.5 million, 2.43% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $11.5 million at Rigel Pharmaceuticals, up from $8.9 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $17.6 million in Q3 2022 and troughed at $1.0 million in Q1 2024.
  • A 5-year average of $9.3 million and a median of $8.8 million in 2025 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 80.32% in 2024 and later soared 641.97% in 2025.
  • Year by year, Other Accumulated Expenses stood at $13.5 million in 2021, then crashed by 63.0% to $5.0 million in 2022, then grew by 6.74% to $5.3 million in 2023, then skyrocketed by 120.3% to $11.8 million in 2024, then dropped by 2.43% to $11.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for RIGL at $11.5 million in Q4 2025, $8.9 million in Q3 2025, and $8.6 million in Q2 2025.